Compare Crispr Therapeutics AG (CRSP) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SOLAI Limited — how do they compare? Crispr Therapeutics AG trades at $50.47 (market cap $4.97B), while SOLAI Limited trades at $3.14 (market cap $14.09M). The key difference: Crispr Therapeutics AG is far larger — about 352.7× SOLAI Limited's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| CRSP | SLAI | |
|---|---|---|
Market Cap | $4.97B | $14.09M |
Sector | Health | Technology |
52-Week High | $76.78 | $30.66 |
52-Week Low | $44.34 | $2.74 |
Enterprise Value | $3.32B | $13.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SLAI trades at $3.24, down 2.99% today, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include the acquisition of a 51% stake in NEURALAND and the launch of Solode Neo AI device. The stock faces NYSE listing standard concerns but shows improved revenue guidance for 2026.
The outlook remains challenged by persistent losses and regulatory risks, though recent acquisitions and product launches offer potential growth catalysts. Investors face significant execution risk amid negative profitability metrics, while technical indicators suggest near-term price support around $3 with resistance at $4.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
